Irish Star on MSNOpinion
Galway woman says 'time is not on our side' in fight for rare disease treatment
Aoife Quinn, 23, was diagnosed with Friedreich's Ataxia at the age of 18.
Difficulty balancing or an inability to do so can be caused by any number of factors. Head injuries, migraines, alcohol use, ear infections and medications can all affect your musculoskeletal system ...
Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Friedreich's Ataxia Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been added to ...
Ataxia has no cure. There are no medications that can specifically treat and cure the symptoms of ataxias. However, medications may ease the symptoms by treating the underlying condition that causes ...
Friedreich’s ataxia is a genetic condition that affects the nervous system. It’s caused by a change in a gene responsible for regulating energy production within cells. This change means that the ...
InvestorsHub on MSN
Design Therapeutics shares jump on encouraging Friedreich ataxia trial results (DSGN)
Stock Surges Following Positive Clinical Update Shares of Design Therapeutics (NASDAQ:DSGN) climbed 27% on Monday after the company released favorable four-week data from its RESTORE-FA clinical trial ...
Ataxia is the defect in normal movements like walking, speaking, eating swallowing etc. It is caused most commonly by damage to the brain stem or cerebellum that regulates movements. There are over 50 ...
AJMC ®: What is your background in treating Friedreich ataxia (FA) in clinical practice and in clinical trials? KUO: I am the director of Columbia University’s ataxia center and have extensive ...
Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The "Ataxia Market Report and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering. The ataxia market size was valued at USD 37.70 ...
Supported by phase 3 trial data showing significant SARA score improvements, levacetylleucine is on track to potentially become the first approved therapy for A-T.
Shares of Design Therapeutics jumped after the company reported positive data from a study of its DT-216P2 drug for Friedreich ataxia, a neuromuscular disease. The stock rose 10% to $15.85 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results